Eric, and good afternoon, everyone. I'll start by briefly summarizing our financials that were reported in our press release earlier today. We reported $139,000,000 in total revenue for the Q3 of 2024, which represents 42% growth versus the prior year quarter. Crysvita contributed $98,000,000 including $56,000,000 from North America, dollars 36,000,000 from Latin America and Turkey and $6,000,000 from Europe. Dejolby contributed $21,000,000 dollars Efkeza contributed $11,000,000 and Mepsevii contributed $10,000,000 Our total operating expenses in the 3rd quarter were $271,000,000 which included R and D expenses of $170,000,000 dollars SG and A expenses of $80,000,000 and cost of sales of $21,000,000 Operating expenses included non cash stock based compensation of $42,000,000 dollars In the Q3, net loss was $134,000,000 or $1.40 per share.